Domchek, Susan M.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 3,294

Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,729

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,655

Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality

Domchek, S. M. (2010) · JAMA

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 1,494

OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 779

Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer

Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D. F., Antoniou, A. C., et al. (2015) · JAMA

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 521

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 343

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L., Barrett, A., Kraya, A. A., Anastopoulos, I. N., Yu, S., et al. (2017) · Nature Communications

BRCA gene mutations in cancerPARP inhibition in cancer therapy

Cited by 296

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

EMBRACE, Kuchenbaecker, K. B., Collaborators, G. S., Breast Cancer Family Registry, HEBON, KConFab Investigators, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, the Consortium of Investigators of Modifiers of BRCA1 and BRCA2, Ramus, S. J., et al. (2015) · Nature Genetics

BRCA gene mutations in cancerOvarian cancer diagnosis and treatment

Cited by 250

Immunotherapy for Breast Cancer: What Are We Missing?

Vonderheide, R. H., Domchek, S. M., & Clark, A. S. (2017) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 233

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., et al. (2011) · British Journal of Cancer

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 232

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

EMBRACE, Dunning, A. M., Collaborators, G. S., HEBON, kConFab Investigators, Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J., et al. (2016) · Nature Genetics

Genetic Associations and EpidemiologyEstrogen and related hormone effects

Cited by 161

Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes

Gallagher, S., Hughes, E., Wagner, S., Tshiaba, P., Rosenthal, E., Roa, B. B., Kurian, A. W., Domchek, S. M., Garber, J., Lancaster, J., et al. (2020) · JAMA Network Open

BRCA gene mutations in cancerGenetic Associations and Epidemiology

Cited by 137

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., et al. (2018) · Gynecologic Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 131

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32, 295 women

EMBRACE, Rebbeck, T. R., HEBON, Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., Apostolou, P., Arnold, N., et al. (2016) · Breast Cancer Research

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 71

Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter?

Shanmugan, S., Sammel, M. D., Loughead, J., Ruparel, K., Gur, R. C., Brown, T. E., Faust, J., Domchek, S., & Epperson, C. N. (2020) · Menopause

BRCA gene mutations in cancerCancer-related cognitive impairment studies

Cited by 46

Olaparib efficacy in patients with germline BRCA ‐mutated, HER2 ‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial

Senkus, E., Delaloge, S., Domchek, S. M., Conte, P., Im, S., Xu, B., Armstrong, A., Masuda, N., Fielding, A., Robson, M., et al. (2023) · International Journal of Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 39